Dry Eye
Conditions
Keywords
keratoconjunctivitis sicca, dry eye, dry eye syndrome, dry eye disease, steroids
Brief summary
Hypothesis: Fluorometholone (FML) 0.1% eyedrops topically applied 4 times a day for 22 days is more efficient than artificial tears (Liquifilm) in dry eye disease (DED) and ameliorates the worsening of the disease after exposure to an adverse controlled environment.
Detailed description
There will be 4 visits in 3 different days: Visit 1 (V1). Inclusion in normalized controlled environment (NCE) Visit 2 (V2). 21 days post-treatment. Data collected in NCE Visit 3 (V3). 21 days post-treatment. Data collected in adverse controlled environment (ACE) Visit 4 (V4). 22 days post-treatment. Recovery visit in ACE. Data collected in NCE
Interventions
DRUGFML 0.1% eyedrops
Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
DRUGLiquifilm artificial tears eyedrops
Liquifilm instillation 4 times a day for 22 days
Sponsors
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Signed informed consent * Subjects refer worsening in their pathologies when exposed to adverse environmental conditions in their daily life * Fluorescein corneal staining ≥ 1in Oxford Scale * Ocular surface disease index (OSDI) test \> 12 * Tear breakup Time (TBT) ≤ 7 seconds in both eyes * Schirmer test without anesthesia ≤ 10 mm in 5 minutes in both eyes * Any concomitant medication that may affect dry eye syndrome, ocular surface or vision, must have started at least 3 months before screening visit, and there are no changes in dose expected during the study duration. * Best corrected visual acuity at least 0.1 logMar at 6 meters with both eyes * Current use of ophthalmic artificial tears at study inclusion. * Signed informed consent * Signed data protection consent
Exclusion criteria
* Sensitivity or known intolerance to any of the products used in the study * Previous severe ocular inflammation or infections in the 6 previous months to study inclusion * Any ocular pathology other than dry eye syndrome or atopic keratoconjunctivitis * Any ocular surgery or trauma that may affect corneal sensitivity and / or normal tear distribution (refractive or cataract surgery) in the 6 previous months or any ocular or systemic surgery planned during the study duration that may affect the study as assessed by principal investigator. * Use of contact lenses in the 3 previous months to study inclusion * Use of any topical medication for pathologies other than dry eye syndrome. * Any ocular topical treatment for dry eye syndrome with corticosteroids or non steroid anti-inflammatory drugs must have stopped 1 month before study inclusion. Any treatment with topical cyclosporin must have been stopped 3 months before study inclusion. * Any uncontrolled severe systemic disease that may affect the eye (except for Sjögren Syndrome) * Start, discontinuation or dose change during the study of antihistaminic, cholinergic agents, beta blockers, antidepressants or any other systemic medications with potential effect over tear film. * Start of any systemic treatment that may affect dry eye syndrome, vision, ocular surface or intraocular pressure during the 3 previous months to study inclusion. * Surgical / non surgical tear point occlusion in the 3 previous months to study inclusion or prevision during study duration for this procedure. * Cup / disc ratio \> 0.6 * History of intraocular pressure \> 22 mm Hg within 2 months previous to study inclusion * Pregnancy or breastfeeding women * Inclusion in another research study in the previous 30 days to study inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fluorescein corneal staining | 22 days | Evidence of statistically significant changes in the number of subjects with an increase ≥ 1 point in fluorescein corneal staining between pre and post adverse condition exposure in ACE (V2 vs V3) and between post adverse condition exposure in ACE and recovery visit (V3 vs V4). |
| Symptom Assessment in Dry Eye (SANDE) I and II questionnaire | 22 days | Evidence of statistically significant changes in the number of subjects with a reduction ≥ 2 points in SANDE score between pre and post adverse condition exposure in ACE (V2 vs V3) and between post adverse condition exposure and recovery visit (V3 vs V4). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biomicroscopy findings at slit lamp examination | 22 days | Biomicroscopy findings (general aspect of ocular surface and anterior segment, plus corneal and conjunctival staining) after 22 days of treatment compared to baseline |
| Adverse events during the trial | 22 days | Adverse events that occur during the trial |
| Tear inflammatory molecule levels | 22 days | Evidence of statistically significant changes between the differences in tear molecule concentrations pre and post adverse condition exposure (V2 vs V3) in ACE and between post adverse condition exposure and recovery visit (V3 vs V4). |
| Intraocular pressure (IOP) and fundus examination | 22 days | Intraocular pressure levels measured with a Goldman tonometer Evaluation of optic disk/cup ratio at fundus examination |
| Other Efficacy Measures | 22 days | Conjunctival Staining (Lissamine Green; Oxford Scale) T-BUT (tear break-up time) Conjunctival hyperemia (Efron Scale) Patient satisfaction with the treatment (VAS 0-100) |
| Best corrected visual acuity | 22 days | Best corrected visual acuity measured with the ETDRS (Eearly Treatment for Diabetes Retinopathy Study) chart after 22 days of treatment compared to baseline |
Countries
Spain
Outcome results
None listed